Jump to ContentJump to Main Navigation
Show Summary Details
More options …

Clinical Chemistry and Laboratory Medicine (CCLM)

Published in Association with the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM)

Editor-in-Chief: Plebani, Mario

Ed. by Gillery, Philippe / Lackner, Karl J. / Lippi, Giuseppe / Melichar, Bohuslav / Payne, Deborah A. / Schlattmann, Peter / Tate, Jillian R.

12 Issues per year


IMPACT FACTOR 2016: 3.432

CiteScore 2016: 2.21

SCImago Journal Rank (SJR) 2016: 1.000
Source Normalized Impact per Paper (SNIP) 2016: 1.112

Online
ISSN
1437-4331
See all formats and pricing
More options …
Volume 49, Issue 10 (Oct 2011)

Issues

Recent progress and clinical importance on pharmacogenetics in cancer therapy

Thomas I. Peng Soh / Wei Peng Yong / Federico Innocenti
  • University of North Carolina at Chapel Hill, Institute for Pharmacogenomics and Individualized Therapy, Chapel Hill, NC, USA
  • Email
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
Published Online: 2011-09-28 | DOI: https://doi.org/10.1515/CCLM.2011.715

Abstract

Recent advances have provided unprecedented opportunities to identify prognostic and predictive markers of efficacy of cancer therapy. Genetic markers can be used to exclude patients who will not benefit from therapy, exclude patients at high risk of severe toxicity and adjust dosing. Genomic approaches for marker discovery now include genome-wide association studies and tumor DNA sequencing. The challenge is now to select markers for which there is enough evidence to transition them to the clinic. The hurdles include the inherent low frequency of many of these markers, the lengthy validation process through trials, as well as legislative and economic hurdles. Attempts to answer questions about certain markers more quickly have led to an increased popularity of trials with enrichment design, especially in light of the dramatic phase I results seen in recent months. Personalized medicine in oncology is a step closer to reality.

Keywords: biomarkers; cancer therapy; pharmacogenetics

About the article

Corresponding author: Federico Innocenti, MD, PhD, University of North Carolina at Chapel Hill, Institute for Pharmacogenomics and Individualized Therapy, 1014 Genetic Medicine Bldg. CB 7361, 120 Mason Farm Rd. Chapel Hill, NC 27599-7361, USA Phone: +1-919-966-9422, Fax: +1-919-966-5863


Received: 2011-05-11

Accepted: 2011-09-01

Published Online: 2011-09-28

Published in Print: 2011-10-01


Citation Information: Clinical Chemistry and Laboratory Medicine, ISSN (Online) 1437-4331, ISSN (Print) 1434-6621, DOI: https://doi.org/10.1515/CCLM.2011.715.

Export Citation

©2011 by Walter de Gruyter Berlin Boston. Copyright Clearance Center

Comments (0)

Please log in or register to comment.
Log in